OncoMatch/Clinical Trials/NCT06005870
Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression
Is NCT06005870 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Zanubrutinib plus RCHOP for diffuse large b cell lymphoma.
Treatment: Zanubrutinib plus RCHOP — This study aim to evaluate the efficacy and safety of zanubrutinib combined with R-CHOP in the treatment of DLBCL patients with p53 protein expression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TP53 overexpression (≥50% by immunohistochemistry)
Patients with positive p53 expression detected by immunohistochemistry (≥50%)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Blood counts
neutrophil count (NEUT) ≥1.5×10^9/L, platelet count (PLT) ≥75×10^9/L, hemoglobin (HGB) ≥80 g/L; G-CSF not used in past 7 days (lymphoma-induced cytopenia could be included)
Kidney function
serum creatinine (Cr) ≤2.0×ULN or creatinine clearance (CCr) ≥60ml/min
Liver function
Total bilirubin (TBIL) ≤1.5× ULN; ALT and AST ≤2.5×ULN; If liver metastases present, TBIL≤3×ULN, ALT and AST≤5×ULN
Cardiac function
LVEF≥50%, ECG did not indicate any acute myocardial infarction, arrhythmia, or atrioventricular conduction block above grade I
The patients had certain conditions of organ function reserve, and the laboratory tests within 1 week before enrollment met the following conditions: ... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06005870 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require TP53?
Yes, TP53 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify